ClinicalTrials.gg
CompletedNCT03936426Updated Apr 20, 2020

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

A Phase 1/2 interventional study of Cu-64 SARTATE and Cu-67 SARTATE in Meningioma, sponsored by Clarity Pharmaceuticals Ltd. Completed at 1 site in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Clarity Pharmaceuticals Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2018, registered Apr 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to investigate the safety and tolerability of a single dose of Cu-64 SARTATE and multiple doses of Cu-67 SARTATE administered to participants with meningioma. All participants in this study will be injected with a single dose of Cu-64 SARTATE to demonstrate how it is absorbed in the body. Then participants will receive individualised doses of Cu-67 SARTATE for up to 4 cycles.

Read the detailed description

This is a single centre, open label, non-randomised, single cohort, multiple dose study of Cu-67 SARTATE administered to male and female participants diagnosed with grade I, II, or III meningioma. The maximum allowable dose will be calculated using dosimetry data acquired from PET/CT scans completed during a pre-treatment diagnostic \& dosimetry phase using Cu-64 SARTATE, a structurally identical molecule radiolabelled with copper-64 (Cu-64), instead of copper-67 (Cu-67). Approximately 6 participants will be enrolled in the study. Participants will have up to 4 therapy cycles (6-12 weeks apart). Safety visits will occur between each cycle at bi-weekly intervals to ensure the participant meets the safety criteria prior to their next therapy. An efficacy assessment will be conducted following cycle 2 to determine if a subsequent 2 cycles of therapy will be administered. Participants who complete all four cycles of Cu-67 SARTATE therapy, will complete their final study visit at 12 weeks post administration of cycle 4.

02

Conditions studied

  • Meningioma

Browse trials for

03

In context

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

This study's enrollment of 5 is below the median of 40 across 180 interventional studies indexed under Meningioma.

Browse Meningioma studies →

Lead sponsor

Clarity Pharmaceuticals Ltd is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Age greater than or equal to 50 years.
  3. greater than or equal to 3 months.
  4. Has adequate organ function as defined by the following laboratory values obtained within 28 days prior to administration of Cu-64 SARTATE:

    1. Estimated (eGFR) greater than 40ml/min as measured using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
    2. (AST) and alanine aminotransferase (ALT) less than 3.0 x (ULN).
    3. less than /=450msec as measured by 12 lead .
  5. (ECOG) performance score of less than or equal to 2.
  6. Diagnosis of recurrent or progressive confirmed WHO grade I-III meningioma which has failed standard of care therapies. Patients will be considered to have failed standard care when they have disease that is progressing despite standard treatment (primarily radiotherapy) or where, in the opinion of their treating physician, further standard therapy is considered to be of sufficiently high risk of complication as to warrant consideration of alternate therapies.
  7. Male participants must agree to use methods from Day 0 through to 4 weeks after the last dose of Cu-67 SARTATE.
  8. A female participant is eligible to participate if she is of:

    1. Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and oestradiol less than 40 pg/ml (less than 140 pmol/l) is confirmatory].
    2. Child-bearing potential and agrees to use contraception methods for an appropriate period of time (as determined by the Investigator) prior to Day 0 to sufficiently minimize the risk of pregnant females being enrolled. These measures are the combination of a barrier method AND established (greater than 2 cycles) hormonal methods (e.g. the oral contraceptive pill). Absolute sexual abstinence may be considered acceptable at the discretion of the investigator. Abstinence for the 12 days prior to therapy to allow for serum B-hCG assessment which should then ensure the patient is not pregnant prior to therapy administration.
    3. Female participants must agree to use contraception until four weeks after the last dose of Cu-67 SARTATE.

Exclusion criteria

Exclusion Criteria:

  1. Known sensitivity or allergy to somatostatin analogues.
  2. Participants who have received interventional treatment for their meningioma within the four weeks prior to Day 0.
  3. Any major surgery within the four weeks prior to Day 0.
  4. Any additional planned interventions, including surgery or radiation therapy that would interfere with safety or efficacy assessments.
  5. Treatment with long acting somatostatin analogues within 28 days prior to Day 0. Treatment with short acting somatostatin analogues within 24 hours prior to Day 0.
  6. Any other in the past 5 years except for cervical intraepithelial neoplasia (CIN) of the cervix, squamous cell carcinoma (SCC) of the skin, basal cell carcinoma (BCC) of the skin or clinical insignificant prostate cancer not requiring prior therapy.
  7. Breastfeeding females and pregnant females.
  8. Treatment with any agent received within four weeks prior to Day 0.
  9. Participants unwilling or unable to comply with protocol requirements.
  10. Urinary or faecal incontinence of sufficient degree to be of concern for contamination risk in the opinion of the Investigator.
  11. Peptide receptor radionuclide therapy (PRRT) at any time prior to enrolment in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    SARTATE

    All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.

    Drug: Cu-64 SARTATE and Cu-67 SARTATE

Interventions

  • DrugCu-64 SARTATE and Cu-67 SARTATE

    Drug page: 64Cu-SARTATEStudies of 64Cu-SARTATE64Cu-SARTATE pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug

    Also known as: SARTATE, copper SARTATE, Cu-SARTATE, 64Cu-SARTATE, 67Cu-SARTATE, Cu-64 SARTATE, Cu-67 SARTATE, 64/67Cu-SARTATE, Cu-64/67 SARTATE

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of multiple doses of Cu-67 SARTATE using CTCAE version 4.03

    Safety will be assessed via vital signs, laboratory tests, physical examinations, ECGs and spontaneous adverse event reporting.

    Time frame: 55 weeks

  2. Safety and tolerability of a single dose of Cu-64 SARTATE using CTCAE version 4.03

    Safety will be assessed via vital signs, laboratory tests, physical examinations, ECGs and spontaneous adverse event reporting.

    Time frame: 56 weeks

Secondary outcomes

  1. Absorbed dose of Cu-64 SARTATE in target, non-target organs and whole body.

    Absorbed doses (mSv/MBq) will be calculated using PET/CT scans acquired at 1, 4 and 24 hours post administration of Cu-64 SARTATE.

    Time frame: 1, 4 and 24 hours post administration of Cu-64 SARTATE.

  2. Absorbed dose of Cu-67 SARTATE in target, non-target organs and whole body.

    Absorbed doses (mSv/MBq) will be calculated using SPECT/CT scans acquired at 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

    Time frame: 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

  3. Maximum and mean SUV of Cu-64 SARTATE in target organs and SSTR binding lesions.

    Maximum and mean SUV will be calculated using PET/CT scans acquired at 1, 4 and 24 hours post administration of Cu-64 SARTATE.

    Time frame: 1, 4 and 24 hours post administration of Cu-64 SARTATE.

  4. Maximum and mean SUV of Cu-67 SARTATE in target organs and SSTR binding lesions.

    Maximum and mean SUV will be calculated using SPECT/CT scans acquired at 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

    Time frame: 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

  5. Activity of Cu-64 SARTATE in target and non-target organs and SSTR binding lesions as a percentage of the administered dose.

    The percentage of the administered dose will be calculated using PET/CT scans acquired at 1, 4 and 24 hours post administration of Cu-64 SARTATE.

    Time frame: 1, 4 and 24 hours post administration of Cu-64 SARTATE.

  6. Activity of Cu-67 SARTATE in target and non-target organs and SSTR binding lesions as a percentage of the administered dose.

    The percentage of the administered dose will be calculated using SPECT/CT scans acquired at 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

    Time frame: 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

  7. Objective Response

    Objective response to therapy will be assessed according to the RANO Response Criteria for Meningioma, as measured by MRI and clinical status.

    Time frame: At 6 weeks post second administration of Cu-67 SARTATE, as well as at 6 and 12 weeks following the fourth administration.

  8. Qualitative analysis of PET/CT scans post administration of Cu-64 SARTATE.

    Qualitative analysis of PET/CT scans to identify uptake patterns.

    Time frame: 1, 4 and 24 hours post administration of Cu-64 SARTATE.

  9. Qualitative analysis of SPECT/CT scans post administration of Cu-67 SARTATE.

    Qualitative analysis of SPECT/CT scans to identify uptake patterns.

    Time frame: 1, 4, 24 and 96 hours post administration of Cu-67 SARTATE.

07

Study locations

1 site
  • Royal North Shore Hospital
    Sydney, New South Wales 2065, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2019, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 3, 2019
StartActual
Jul 9, 2018
Primary completionActual
Sep 19, 2019
CompletionActual
Sep 19, 2019
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03936426
Lead sponsor
Clarity Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Jul 9, 2018
Primary completion
Sep 19, 2019
Completion
Sep 19, 2019
Last update
Apr 20, 2020

Study contacts

Geoffrey Schembri, MD
principal investigator · Royal North Shore Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 64Cu-SARTATE

Start the discussion